Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor

Ophthalmology. 2021 Apr;128(4):624-626. doi: 10.1016/j.ophtha.2020.08.026. Epub 2020 Sep 1.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / adverse effects*
  • Corneal Diseases / chemically induced*
  • Corneal Diseases / diagnosis
  • Drug-Related Side Effects and Adverse Reactions / diagnosis
  • Drug-Related Side Effects and Adverse Reactions / etiology*
  • Female
  • Humans
  • Male
  • Osteomalacia / drug therapy
  • Paraneoplastic Syndromes / drug therapy
  • Phenylurea Compounds / adverse effects*
  • Prospective Studies
  • Protein Kinase Inhibitors / adverse effects*
  • Pyrimidines / adverse effects*
  • Receptor, Fibroblast Growth Factor, Type 1 / antagonists & inhibitors*

Substances

  • Antineoplastic Agents
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Pyrimidines
  • infigratinib
  • Receptor, Fibroblast Growth Factor, Type 1

Supplementary concepts

  • Oncogenic osteomalacia